- Your cart is empty
- Continue Shopping
Mounjaro vs Wegovy: Which Weight Loss Injection Is Best in the UK? (2026 Comparison)
- All meds
- Posted on
-
by @zohaib@007_123@
- 0 comments
The search for effective medical weight management in the UK is currently dominated by two licensed weekly injections: Mounjaro (tirzepatide) and Wegovy (semaglutide). With regulatory updates, dose expansions, and pricing adjustments shifting the landscape, choosing between these GLP-1 and dual-action treatments requires understanding how they differ in mechanism, efficacy, and suitability.
Here is a side-by-side comparison of Mounjaro and Wegovy based on recent clinical trial data and UK prescribing guidelines.
At a Glance: Mounjaro vs Wegovy
| Feature | Mounjaro (Tirzepatide) | Wegovy (Semaglutide) |
| Active Ingredient | Tirzepatide | Semaglutide |
| Mechanism | Dual agonist (GLP-1 + GIP) | Single agonist (GLP-1) |
| UK License for Weight Loss | Yes (Approved by MHRA / NICE) | Yes (Approved by MHRA / NICE) |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Dose Escalation Range | 2.5 mg to 15 mg | 0.25 mg up to 2.4 mg (or 7.2 mg) |
| Average Weight Loss | ~20.2% to 22.5% (SURMOUNT-5 / SURMOUNT-1) | ~13.7% to 15% (2.4 mg) / up to 20.7% (7.2 mg) |
| Typical Monthly Cost (Private) | £130 – £375 (varies by dose) | £124 – £324 (varies by dose) |
1. How They Work: Dual-Action vs Single-Action
The primary difference between the two medications lies in their biological target:
- Wegovy (Semaglutide): Mimics GLP-1 (glucagon-like peptide-1), a hormone produced in the gut that slows stomach emptying, increases feelings of fullness, and reduces appetite signals in the brain.
- Mounjaro (Tirzepatide): Acts as a GIP and GLP-1 receptor agonist. By targeting glucose-dependent insulinotropic polypeptide (GIP) alongside GLP-1, Mounjaro delivers a dual mechanism that enhances insulin sensitivity and provides stronger appetite suppression signals.
2. Efficacy: Head-to-Head Trial Results
In clinical trials evaluating weight loss outcomes, both medications outperformed traditional lifestyle interventions alone, with tirzepatide showing a higher average weight loss overall:
- SURMOUNT-5 Trial: Direct head-to-head comparisons showed that participants taking the maximum dose of tirzepatide achieved an average weight loss of 20.2% over 72 weeks, compared to 13.7% for semaglutide 2.4 mg.
- Higher Wegovy Doses: The approval of higher semaglutide maintenance options (up to 7.2 mg) has narrowed this gap for specific patient groups, yielding average reductions near 20.7% in higher-dose trials.
3. Side Effects and Tolerability
Because both medications act on the gastrointestinal tract by slowing digestion, their side effect profiles are very similar:
- Common Side Effects: Nausea, constipation, diarrhoea, acid reflux, abdominal pain, and headache.
- Tolerability: Side effects are generally most pronounced during dose escalation (titration) and tend to settle as the body adjusts.
- Important Safety Notes:
- Both medications require screening for history of pancreatitis or severe gastrointestinal disease.
- Mounjaro may reduce the efficacy of oral contraceptives during dose escalation; additional barrier methods or alternative contraception are recommended.
4. UK Access and Pricing
Both treatments are available in the UK via private prescriptions through GPhC-registered pharmacies, with restricted access on the NHS based on specific BMI and comorbidity thresholds:
- Pricing Factors: Both medications follow a stepped pricing structure, where initial low-dose starter pens cost less, while maintenance doses sit at the higher end of the price spectrum.
- Selection Criteria: Higher average weight loss numbers make Mounjaro a primary choice for significant weight reduction, whereas Wegovy remains an established option—particularly for individuals who tolerate semaglutide well or have existing cardiovascular risk factors where GLP-1 evidence is well-documented.
Q: Which medication is better for weight loss, Mounjaro or Wegovy?
A: Clinical trial data shows that Mounjaro (tirzepatide) yields higher average total body weight loss (~20% to 22.5%) compared to standard Wegovy 2.4mg (~15%). However, with the introduction of Wegovy’s higher 7.2mg maintenance option, average results for semaglutide reach up to 20.7%, significantly narrowing the performance gap. Individual results depend on your tolerability and adherence.
Q: Can I switch directly from Wegovy to Mounjaro (or vice versa)?
A: Yes, under medical supervision. The standard clinical protocol in the UK requires stopping your current injection and waiting at least 7 days before initiating the new treatment. This allows the active ingredient to clear your system. Depending on your current dose and side-effect history, a doctor will determine whether you start at the base dose or step onto a higher tier.
Q: Do I need extra contraception while on Mounjaro?
A: Yes, if you use oral contraceptives. Mounjaro delays gastric emptying, which can temporarily decrease the absorption and efficacy of oral birth control pills. Prescribers recommend using a barrier method (like condoms) or switching to a non-oral contraceptive for 4 weeks after starting Mounjaro and for 4 weeks following every dose increase. Wegovy does not carry this specific restriction.
Q: How much do Mounjaro and Wegovy cost per month privately in the UK?
A: Prices vary by dose tier and pharmacy provider. Lower starter doses for both medications typically range from £100 to £150 per month, while higher maintenance doses (such as Mounjaro 15mg or Wegovy 2.4mg/7.2mg) generally range between £200 and £375 per month.
Q: Can I get Mounjaro or Wegovy on the NHS?
A: Both medications are approved by NICE (TA875 for Wegovy and TA1026 for Mounjaro), but NHS access remains strictly limited. Eligibility typically requires a high BMI (usually 35+ with weight-related health conditions, or 30+ under specific clinical criteria) alongside a referral to tier 3 specialist weight management services.
